Two-thirds of people living with HIV would like to try injectable treatment
Two-thirds of people on HIV treatment would like to switch to a long-acting injectable regimen, according to a four-country survey presented to the virtual HIV Glasgow conference this week. Healthcare professionals answering the same survey thought fewer people – a quarter – would end up switching.
The survey was run on behalf of ViiV Healthcare, who make injectable cabotegravir/rilpivirine, so it might be expected to come up with a favourable result. However, an independently run Italian survey found an even greater level of interest, with 89% of respondents being interested in injectables.
Read more here